Company Shares of Anthera Pharmaceuticals (NASDAQ:ANTH) Rally 19.81%

Anthera Pharmaceuticals (NASDAQ:ANTH) : Traders are bullish on Anthera Pharmaceuticals (NASDAQ:ANTH) as it has outperformed the S&P 500 by a wide margin of 10.28% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 18.3%, relative to the S&P 500. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 19.81% in the last 1 week, and is up 12.06% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.

The company shares have dropped -53.31% from its 1 Year high price. On Jul 24, 2015, the shares registered one year high at $11.65 and the one year low was seen on Feb 8, 2016. The 50-Day Moving Average price is $3.38 and the 200 Day Moving Average price is recorded at $3.52.

The stock has recorded a 20-day Moving Average of 19.91% and the 50-Day Moving Average is 12.77%.


Anthera Pharmaceuticals (NASDAQ:ANTH): stock turned positive on Friday. Though the stock opened at $3.51, the bulls momentum made the stock top out at $3.94 level for the day. The stock recorded a low of $3.48 and closed the trading day at $3.81, in the green by 12.72%. The total traded volume for the day was 2,187,146. The stock had closed at $3.38 in the previous days trading.

In an insider trading activity,The (Chief Medical Officer) of Anthera Pharmaceuticals Inc, Hislop Colin sold 12,500 shares at $5.31 on November 13, 2015. The Insider selling transaction had a total value worth of $66,375. The Insider information was disclosed with the Securities and Exchange Commission in a Form 4 filing.

Anthera Pharmaceuticals Inc. (Anthera) is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation and autoimmune diseases. The Companys primary Phase 3 product candidate blisibimod targets elevated levels of Bcell activating factor (BAFF) which has been associated with a variety of Bcell mediated autoimmune diseases including systemic lupus erythematosus or lupus IgA nephropathy lupus nephritis multiple myeloma and others. The Companys second product candidate Sollpura (liprotamase) is a Phase III investigational pancreatic enzyme replacement therapy (PERT) intended for the treatment of patients with exocrine pancreatic insufficiency (EPI) often seen in patients with cystic fibrosis and other conditions.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *